Caris Life Sciences saw a sharp drop in its stock price, which has raised concerns among investors.
Caris Life Sciences, Inc. Common Stock (NASDAQ:CAI) fell 7.44% yesterday, closing at CA$28.35. This decline is a significant setback for the company, which has been focused on ambitious growth plans.
Advertisement
Caris Life Sciences, Inc. Common Stock
CAI.US
CAI.US
Caris Life Sciences, Inc. Common Stock
WealthAwesomeMarket cap
$8.66B
P/E
3.2x
52W high
$33.66
52W low
$14.19
1W change
-12.15%
Analyst Price Targets
Based on analyst covering CAI · as of Sep 23, 2026
Wall Street analysts forecast CAI stock price to rise 140669.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$28.15
+140669.5% Upside
Previously C$27.54 on Sep 17, 2026
Current Price
C$0.02
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CAI's historical volatility
30-Day Vol
65.9%
Annualized
90-Day Vol
70.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$33.89
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$30.09 | C$23.97 – C$37.77 |
| 60 trading days | C$31.93 | C$23.15 – C$44.05 |
| 90 trading days | C$33.89 | C$22.86 – C$50.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Caris Life Sciences' upcoming financial reports and strategic partnerships, as the recent stock performance raises questions about its future direction.
Bull case
Caris Life Sciences reported a remarkable 97% revenue increase in 2025 and is projecting revenues between $1.0 to $1.02 billion for 2026. This indicates strong growth potential.
Bear case
Despite the positive revenue forecasts, the recent stock drop reflects investor skepticism about the company's ability to execute its ambitious plans and sustain its momentum.
Stock Performance Overview
Advertisement
Caris Life Sciences, Inc. Common Stock experienced a notable decline yesterday, closing at CA$28.35. The 7.44% drop raises alarms about investor confidence in the company's future, especially given its ambitious revenue projections.
Future Outlook and Investor Sentiment
Even with a reported 97% revenue increase in 2025 and optimistic projections for 2026, the recent stock drop shows that investors are still cautious. The market's reaction suggests that stakeholders are questioning whether Caris can deliver on its growth promises.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
